News Search Results
Sep 04, 2025, 08:05 ET Lactiga Wins NIH Backing for First-in-Class Breastmilk-Derived Antibody in Inflammatory Bowel Disease
BRUNSWICK, N.J., Sept. 4, 2025 /PRNewswire/ -- Lactiga US, Inc., a biotechnology company developing a first-in-class mucosal antibody, announced today it has received an award from the National Institutes of Health (NIH), National
More news about: Lactiga US, Inc.
Sep 04, 2025, 08:00 ET Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial
MONTREAL, Sept. 4, 2025 /PRNewswire/ -- Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity,
More news about: Congruence Therapeutics
Sep 04, 2025, 08:00 ET Dr Francesca Rapino of THERAtRAME SA named in Business Worldwide Magazines 2025 CEO Awards
PhD, has been recognised for her outstanding achievements in advancing oncology therapeutics through innovative approaches in the biotechnology sector. The 2025 CEO Awards celebrate exceptional leaders who are redefining industries and setting new standards in leadership,
More news about: Business Worldwide Magazine
Sep 04, 2025, 08:00 ET Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
Sept. 4, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced
More news about: Coya Therapeutics, Inc.
Sep 04, 2025, 07:58 ET VLCC Unveils The Great Indian Beauty Festival 2025 - India's Biggest Beauty Celebration of the Year
booster powered by polynucleotides and the Hymagic™-4D hyaluronic acid complex for deep hydration and tissue repair, and AnteAGE MD®, a breakthrough biotechnology treatment that uses stem cell-derived growth factors and cytokines to promote skin health and rejuvenation. Speaking on the occasion, Taniya
More news about: VLCC
Sep 04, 2025, 07:30 ET Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Sep 04, 2025, 07:00 ET Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Sep 04, 2025, 07:00 ET Syantra, Inc., announces new therapeutic division for immuno-oncology drug discovery, leveraging its patent-pending Onco-ID™ platform
CALGARY, AB, Sept. 4, 2025 /PRNewswire/ - Syantra, Inc., a biotechnology company revolutionizing cancer detection, today announced a new therapeutic division that will focus on developing first-in-class therapies to help
More news about: Syantra Inc.
Sep 04, 2025, 06:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 04, 2025, 06:30 ET Immunic to Participate in Investor and Scientific Conferences in September
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Sep 04, 2025, 06:00 ET Waterdrop Inc. Announces Second Quarter 2025 Unaudited Financial Results and a Cash Dividend
clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution
More news about: Waterdrop Inc.
Sep 04, 2025, 05:00 ET Rapid Food Safety Testing Market worth $31.22 billion by 2030 - Exclusive Report by MarketsandMarkets™
biotechnology to express desired traits such as
More news about: MarketsandMarkets
Sep 03, 2025, 19:00 ET Nektar Therapeutics to Participate in Two Investor Conferences in September
conferences, please reach out to your respective representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Sep 03, 2025, 16:09 ET PLPC-DB™: Non-Cellular Oncology Immunotherapy with STIP-NAM Traceability, Entering a Global Acquisition Window.
for immediate acquisition, subject to due diligence and binding agreements. About OGRD AllianceOGRD Alliance is a global biotechnology group focused on advancing next-generation immunology platforms. With over a decade of research and a strong international regulatory framework,
More news about: OGRD Alliance
Sep 03, 2025, 14:00 ET BioFactura Launches Capitol Biologics - New CDMO Division to Accelerate Biologics Development from Concept to Clinic
Organization (CDMO) division dedicated to supporting the process development, early‑phase clinical manufacturing, and analytical needs of emerging biotechnology companies and U.S. government agencies. Strategically located in the BioHealth Capital Region, Capitol Biologics combines technical excellence,
More news about: BioFactura
Sep 03, 2025, 13:38 ET Seven Rubin and Rudman Partners Named to 2025 Lawdragon 500 Leading Global Real Estate Lawyers
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Sep 03, 2025, 11:43 ET Liebherr unveils New High-Performance refrigerators and freezers for use in research applications
The new series is specifically designed to meet the rigorous demands of biotechnology and pharmaceutical research environments. With a seamless chrome-nickel steel interior, these refrigerators and freezers offer exceptional durability,
More news about: Liebherr Appliances USA
Sep 03, 2025, 10:30 ET GMP Cell Therapy Consumables Market to Reach USD 114.4 Million by 2035, with CAGR 28.9% Driven by Advanced Cell Therapy and Biopharmaceutical Innovation | Vantage Market Research
medicine initiatives. Brazil is a key growth driver with expanding biopharma infrastructure. Increasing investment in biotechnology, medical research, and hospital-based cell therapy programs is strengthening opportunities for GMP consumables in the region. What Role
More news about: Vantage Market Research
Sep 03, 2025, 10:15 ET Swine Influenza Vaccines Market Projected to Reach USD 750 Billion by 2033 Driven by Advancements in Animal Health, Rising Swine Population - Market Research Intellect
Growing global demand for pork products fuels the need for healthier and more productive livestock, thereby increasing vaccine usage. Advances in biotechnology, such as recombinant DNA technology and mRNA platforms, open pathways for more effective, long-lasting vaccines. The integration of vaccines with
More news about: Market Research Intellect
Sep 03, 2025, 10:15 ET Rotavirus Vaccine Market Is Projected to Reach USD 3.5 Billion by 2033 Driven by Rising Immunization Programs and Increasing Healthcare Awareness - Market Research Intellect
impactful in low-resource settings, where storage and transportation challenges are significant barriers. Additionally, collaborations between biotechnology firms and healthcare organizations are accelerating clinical trials to expand product portfolios. The focus on developing combination vaccines that
More news about: Market Research Intellect
Sep 03, 2025, 10:10 ET Heterocyclic and Fluoro Organic Compounds Market to Reach $1,213.5 Million by 2035, Growing at 7.2% CAGR - Vantage Market Research
in laboratory research, pharmaceutical development, and chemical synthesis underpins this leadership. Reagents are integral to drug screening, biotechnology research, and high-purity compound production. Growing investments in R&D across pharmaceuticals, electronics, and agrochemicals are expected
More news about: Vantage Market Research
Sep 03, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
[Click here for information about joining the class action] Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S. The Company is developing, among other
More news about: Pomerantz LLP
Sep 03, 2025, 09:50 ET Pearl Meyer Adds Managing Director Will Cockle To Its Growing Technology Executive Compensation Practice
specializes in the technology and life sciences sectors, with a focus on software, emerging technologies, fintech, clean energy, and biotechnology. A frequent speaker at industry conferences on compensation and corporate governance trends, he holds a BSBA from Washington
More news about: Pearl Meyer
Sep 03, 2025, 09:02 ET Cellcosmet Unveils Next-Generation Brightening Duo for Complete Hyperpigmentation Defense
formulas in accordance to exacting, rigorous specifications and in keeping with the most recent scientific discoveries. Cellcosmet's command of biotechnology and expertise in cellular and microbiome science as well as botanical and marine ingredients enable the brand to formulate exceptional product offerings
More news about: Cellcosmet
Sep 03, 2025, 09:00 ET Cizzle Bio CEO Bill Behnke Named by CXO Outlook® as "Most Inspiring Business Leader 2025" for Advancing Breakthrough Early Cancer Detection Blood Tests
SAN ANTONIO, Sept. 3, 2025 /PRNewswire/ -- Cizzle Bio, Inc., a biotechnology company advancing innovative biomarker blood tests for early detection of lung and gastric cancers, announced today that its founder and CEO,
More news about: Cizzle Bio